Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination therapy with glutaminase inhibitors and immuno-oncology agents

Combination therapy with glutaminase inhibitors and immuno-oncology agents

US Patent 10258619 · Granted Apr 16, 2019

Estimated economic value: $3,268,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Arginase inhibitor combination therapies2022
Arginase inhibitor combination therapies2022
2,4-pyrimidinediamine compounds and their uses2021
Combination therapy with glutaminase inhibitors and immuno-oncology agents2021
Combination therapy with glutaminase inhibitors and immuno-oncology agents2021
Combination therapy with glutaminase inhibitors and immuno-oncology agents2021
Combination therapy with glutaminase inhibitors and immuno-oncology agents2021
Combination therapy with glutaminase inhibitors and immuno-oncology agents2021
Compositions and methods for inhibiting arginase activity2021
2,4-pyrimidinediamine compounds and their uses2020
2,4-pyrimidinediamine compounds and their uses2020
2,4-pyrimidinediamine compounds and their uses2020